Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6090098rdf:typepubmed:Citationlld:pubmed
pubmed-article:6090098lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C0036770lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C0032005lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C0021463lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C0034596lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:6090098lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:6090098pubmed:issue4lld:pubmed
pubmed-article:6090098pubmed:dateCreated1984-11-1lld:pubmed
pubmed-article:6090098pubmed:abstractTextWe have previously demonstrated that binding of partially purified, 3H-labeled Sertoli cell factor (SCF) to rat anterior pituitary homogenates was tissue specific, saturable, time and temperature dependent, and competitively inhibited by unlabeled SCF. The present study further characterized the binding of [3H]SCF to rat anterior pituitary in vitro and explored its potential use as a radioreceptor assay for SCF and other inhibin preparations. [3H]SCF was synthesized by rat Sertoli cells cultured in the presence of [3H]leucine (5 mu Ci/ml) and was then partially purified by Sephadex gel filtration and high pressure liquid chromatography. The purified [3H]SCF had a specific activity of approximately 20,000 dpm/micrograms protein and was biologically active in pituitary cell cultures. The binding was carried out in 0.5 ml buffer, containing one pituitary equivalent and, wherever appropriate, various unlabeled competing substances. The binding was optimal at pH 7.4 and was decreased by pretreatment of [3H]SCF with trypsin (0.25%; 37 C; 30 min) or heat (100 C; 10 min). Storage of the pituitary glands at -20 C for several months and differences in animal age did not affect total binding per pituitary, but the amount of radioactivity bound per mg pituitary tissue declined progressively between 18-90 days of age. Over 90% of the bound [3H]SCF was competitively inhibited by excess unlabeled SCF and several other inhibin preparations of testicular origin: high mol wt fraction of ram testis fluid (mol wt, greater than 10,000), low mol wt fraction of ram testis fluid (mol wt, less than 5,000), ovine testicular lymph, and aqueous rat testicular extract. The degree of inhibition was dose dependent, and except for the low mol wt fraction of ram testis fluid, the displacement curves were parallel (slope, 0.95). In contrast, various noninhibin substances tested [rat androgen-binding protein, bovine LH, BSA, native GnRH, or GnRH agonist analogs D-Ser-(tBu)6-des-Gly10-GnRH-N-EA and D-Ala6-des-Gly10-GnRH-N-EA] did not significantly compete for the [3H]SCF binding. The binding ability correlated well with inhibin biological activity in vitro. These results provide additional evidence for the presence of SCF-binding sites in the rat anterior pituitary which interact with several different inhibin preparations of testicular origin but appear to be distinct from GnRH-binding sites. Our results also indicate that the pituitary binding may be used as a rapid radioreceptor assay for SCF and various other inhibin preparations.lld:pubmed
pubmed-article:6090098pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:languageenglld:pubmed
pubmed-article:6090098pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:citationSubsetAIMlld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6090098pubmed:statusMEDLINElld:pubmed
pubmed-article:6090098pubmed:monthOctlld:pubmed
pubmed-article:6090098pubmed:issn0013-7227lld:pubmed
pubmed-article:6090098pubmed:authorpubmed-author:SteinbergerAAlld:pubmed
pubmed-article:6090098pubmed:authorpubmed-author:Seethalakshmi...lld:pubmed
pubmed-article:6090098pubmed:authorpubmed-author:SteinbergerEElld:pubmed
pubmed-article:6090098pubmed:issnTypePrintlld:pubmed
pubmed-article:6090098pubmed:volume115lld:pubmed
pubmed-article:6090098pubmed:ownerNLMlld:pubmed
pubmed-article:6090098pubmed:authorsCompleteYlld:pubmed
pubmed-article:6090098pubmed:pagination1289-94lld:pubmed
pubmed-article:6090098pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:meshHeadingpubmed-meshheading:6090098-...lld:pubmed
pubmed-article:6090098pubmed:year1984lld:pubmed
pubmed-article:6090098pubmed:articleTitlePituitary binding of 3H-labeled Sertoli cell factor in vitro: a potential radioreceptor assay for inhibin.lld:pubmed
pubmed-article:6090098pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6090098pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6090098lld:pubmed